





PHARMACEUTICAL 2018

ELI LILLY & Co
Rank 212 of 342



The relative strengths and weaknesses of ELI LILLY & Co are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ELI LILLY & Co compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 70% points. The greatest weakness of ELI LILLY & Co is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 95% points.

The company's Economic Capital Ratio, given in the ranking table, is 51%, being 5.4% points above the market average of 46%.

| Input Variable | Value in 1000 USD |
|---|-------------------|
| Assets, Current | 19,202,100 |
| Cost of Goods Sold | 0 |
| Intangible Assets | 8,399,300 |
| Liabilities, Current | 14,535,900 |
| Liabilities, Non-Current | 18,777,200 |
| Other Assets | 8,553,100 |
| Other Compr. Net Income | 174,500 |
| Other Expenses | 11,205,500 |
| Other Liabilities | 0 |
| Other Net Income | 0 |
| Other Revenues | 22,871,300 |
| Property and Equipment | 8,826,500 |
| Research and Development | 5,281,800 |
| Selling, General and Administrative Expense | 6,588,100 |

| Output Variable | Value in 1000 USD |
|--------------------------|-------------------|
| Assets | 44,981,000 |
| Liabilities | 33,313,100 |
| Expenses | 23,075,400 |
| Revenues | 22,871,300 |
| Stockholders Equity | 11,667,900 |
| Net Income | -204,100 |
| Comprehensive Net Income | -116,850 |
| Economic Capital Ratio | 51% |